180
Participants
Start Date
March 19, 2024
Primary Completion Date
October 3, 2025
Study Completion Date
December 26, 2025
Cagrilintide
Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide
Participants will receive once-weekly semaglutide subcutaneously.
Placebo
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Szent Margit Rendelőintézet Nonprofit Kft., Budapest
PVN Kutato Kft., Budapest
Belinus Bt., Debrecen
Borbánya Praxis E.Ü. Kft., Nyíregyháza
CHC Zvezdara, Clinical department for endocrinology, Belgrade
Clinical Hospital Center Bezanijska Kosa, Belgrade
Clinical Hospital Centre Zemun, Belgrade
King Fahad Medical City, Riyadh
King Khaled University Hospital,King Saud Univ. Med. City, Riyadh
King Salman Bin Abdulaziz Hospital, Riyadh
Southgate Medical Group, LLP, West Seneca
Policlinic for diabetes, Zaječar
IRCCS Ospedale San Raffaele Milano, Milan
National Guard Hospital - Jeddah, Jeddah
TPMG Clinical Research, Newport News
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
Headlands Research Orlando, Orlando
Encore Medical Research LLC, Hollywood
Encore Medical Research of Weston, Weston
King Abdulaziz Hospital-Al Ahsa-National Guard, Al Ahsa
Holston Medical Group, Kingsport
Arcturus HC PLC Troy Med Res, Troy
Alliance for Multispec Res, Newton
Velocity Clinical Res-Dallas, Dallas
Sugar Lakes Family Practice PA, Sugar Land
Consano Clinical Research, LLC, Shavano Park
Northeast Clinical Research of San Antonio, San Antonio
Headlands Research Brownsville, Brownsville
Valley Diab. & Endo Comp Ctr, Weslaco
Policlinico Mater Domini Università di Catanzaro, Catanzaro
Nat Res Inst Huntington Park, Huntington Park
Valley Clinical Trials, Inc., Northridge
Southern California Dermatology, Santa Ana
Chinese People's Liberation Army General Hospital-Endocrinology, Beijing
The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing
The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang
Jinan Central Hospital, Ji'Nan
Jinan Central Hospital Affiliated to Shandong University, Jinan
Brigham & Women's Hospital, Boston
Azienda Ospealiero Universitaria Policlinico Umberto I, Roma
Centrum Medyczne Medyk Sp. z o.o., Rzeszów
Osteo-Medic s.c. A. Racewicz, J. Supronik, Bialystok
Renew Clinic Sp. z o.o., Bialystok
Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A., Lodz
NBR Polska Tomasz Klodawski, Warsaw
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji, Warsaw
Velocity Nova Sp. z o.o., Zamość
Lead Sponsor
Novo Nordisk A/S
INDUSTRY